Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.70 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.61 |
| ▸ | C1R | P00736 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282843 | 0.82 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL29098688 | 0.79 | ELANE (0.60) | ELANEPBRM1C1RPARP1 | |
| SCHEMBL26672043 | 0.79 | ELANE (0.70) | ELANEPARP1 | |
| SCHEMBL23881485 | 0.79 | ELANE (0.70) | ELANE | |
| SCHEMBL19189656 | 0.79 | ELANE (0.70) | ELANE | |
| SCHEMBL26438921 | 0.79 | ELANE (0.56) | ELANEPBRM1C1RPARP1 | |
| SCHEMBL9984683 | 0.77 | ELANE (1.00) | ELANEPBRM1C1R | |
| SCHEMBL10069984 | 0.77 | ELANE (0.66) | ELANE | |
| SCHEMBL13206696 | 0.77 | ELANE (1.00) | ELANEC1R | |
| SCHEMBL24743518 | 0.76 | PBRM1 (1.00) | ELANEPBRM1C1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426683-B1 | BENZODIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070912-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260008781-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250388586-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4408848-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-12365687-B2 | Benzodiazepine derivatives as GABA A gamma 1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12344614-B2 | Benzodiazepine derivatives as GABA a GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2025-07-01 | — | — | US | disclosed |
| CN-115677803-B | Preparation method of glycoside derivative containing quinazoline structure and composition thereof and application of glycoside derivative and composition for preventing and treating kiwi fruit canker | 贵州理工学院 | 2025-03-28 | — | — | CN | disclosed |
| EP-4518910-A1 | PET TRACERS FOR VISUALIZING GABAA GAMMA1 RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2025-03-12 | — | — | EP | disclosed |
| US-20250049967-A1 | PET TRACERS FOR VISUALIZING GABAA GAMMA1 RECEPTORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-13 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
| EP-0980374-B1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PFIZER HOLDING FRANCE (FR) | 2003-02-12 | — | — | EP | disclosed |
| US-6239130-B1 | ASTHMA, ATOPIC DERMATITIS, RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISORDERS, PULMONARY HYPERTENSION, LIVER INJURY, BONE LOSS, SEPTIC SHOCK, OR MULTIPLE SCLEROSIS, | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-0789701-B1 | SUBSTITUTED TETRACYCLIC AZEPINE DERIVATIVES WHICH HAVE AFFINITY FOR 5-HT2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2001-02-07 | — | — | EP | disclosed |
| EP-0980374-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049169-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 1998-11-05 | — | — | WO | disclosed |
| EP-0789701-A1 | SUBSTITUTED TETRACYCLIC AZEPINE DERIVATIVES WHICH HAVE AFFINITY FOR 5-HT2 RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-20 | — | — | EP | disclosed |
| US-5552399-A | TREATMENT OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS, GASTROINTESTINAL DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-03 | — | — | US | disclosed |
| WO-1996014320-A1 | SUBSTITUTED TETRACYCLIC AZEPINE DERIVATIVES WHICH HAVE AFFINITY FOR 5-HT2 RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365687-B2 | Benzodiazepine derivatives as GABA A gamma 1 PAM | GABRA1, GABRB1, GABRG1 | ELANE 4674/4885PBRM1 218/4885C1R 2482/4885 |
| US-20250388586-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRA6 | ELANE 4176/4885PBRM1 356/4885C1R 1008/4885 |
| US-12344614-B2 | Benzodiazepine derivatives as GABA a GAMMA1 PAM | GABRA1, GABRB1, GABRA5 | ELANE 4639/4885PBRM1 209/4885C1R 2039/4885 |
| US-20250049967-A1 | PET TRACERS FOR VISUALIZING GABAA GAMMA1 RECEPTORS | GABRA1, GABRG1, GABRB1 | ELANE 4842/4885PBRM1 430/4885C1R 4303/4885 |
| US-20260008781-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRA6, GABRB1 | ELANE 4307/4885PBRM1 397/4885C1R 1044/4885 |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | ELANE 2050/4885PBRM1 2837/4885C1R 106/4885 |
| US-20260070912-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRA6 | ELANE 4415/4885PBRM1 364/4885C1R 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.